AAV

#AAV #Advanced Therapies #CAR-T #Cell and gene therapy #Cell therapy #Drug development #Drug discovery #Gene therapy #RNA

Keep up to date: DDW Highlights 30 January 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Cell and gene therapies have been making the news this week, as… Read More

#News

#AAV #Advanced Therapies #CAR-T #Cell and gene therapy #Cell therapy #Drug development #Drug discovery #Gene therapy #RNA

This week in drug discovery (23-27 January)

News round-up for 23-27 January by DDW Digital Content Editor Diana Spencer. Cell and gene therapies have been making the news this week, as we launch our very own guide to global… Read More

#News

EMA
#AAV #Cell and gene therapy #European Medicines Agency #Forge Biologic #Gene therapy #Priority Review

EMA prioritises AAV gene therapy for Krabbe disease

The European Medicines Agency (EMA) has granted priority medicines (PRIME) designation to FBX-101, Forge Biologic’s adeno-associated virus (AAV) drug candidate for treating patients with Krabbe disease.  PRIME is a regulatory designation by the EMA that provides early and proactive support to developers of promising medicines, to advance and speed up… Read More

#News #Regulatory

#AAV #Cell and gene therapy #Drug delivery #Gene delivery #Gene therapy #mRNA #Nanomedicine / nanotechnology #Ophthalmology

Lipid nanoparticles and mRNA used to treat hereditary blindness

Oregon State University College of Pharmacy scientists have shown that lipid nanoparticles and messenger RNA could treat blindness associated with a rare genetic condition.  Researchers developed nanoparticles able to penetrate the neural retina and deliver mRNA to the photoreceptor cells whose proper function makes vision possible. … Read More

#News #Trending News

AAV gene therapy
#AAV #Animal models #CANbridge Pharmaceuticals #Cell and gene therapy #China #Gene therapy #License agreement #Muscular dystrophy

Chinese biotech company consolidates gene therapy portfolio

CANbridge Pharmaceuticals has exercised its option to secure the exclusive global rights to develop, manufacture and commercialise a novel gene therapy to treat spinal muscular atrophy (SMA) from UMass Chan Medical School.  Animal data presented in 2022 showed that the gene therapy outperformed the benchmark therapy along… Read More

#News

#AAV #Cell and gene therapy #Gene therapy

Accelerating gene therapy research with AAV detection kits 

PerkinElmer has launched ready-to-use adeno-associated virus vectors (AAV) detection kits to support researchers working on gene therapies for a variety of serious diseases.   The validated and fully automatable assays are built on PerkinElmer’s AlphaLISA technology which requires no separation and are optimised, no-wash AAV detection assays. Read More

#News

MHRA
#AAV #Geographic atrophy #MHRA #Therapeutics

Green light for potential AAV gene therapy 

Complement Therapeutics’ lead asset CTx001, an AAV-based gene therapy for the treatment of geographic atrophy (GA), has been awarded an Innovation Passport by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA).  CTx001 was awarded the Innovation Passport based on three criteria: that the condition addressed is seriously debilitating with… Read More

#News #Regulatory

Dementia
#AAV #Cell and gene therapy #Cell and Gene Therapy Catapult #Dementia

New partnership looks to gene therapy for dementia  

The Cell and Gene Therapy Catapult (CGT Catapult) has partnered with the UK Dementia Research Institute (UK DRI) to help advance the development of adeno-associated virus (AAV) based gene therapies for dementia.  Through the collaboration, the CGT Catapult will work with UK academic centres and the UK… Read More

#News

#AAV #Drug discovery #Drug screening #NanoTemper Technologies

NanoTemper Technologies updates AAV/drug discovery portfolio  

NanoTemper Technologies has launched a number of updates to its portfolio of instruments to help researchers working in drug discovery and adeno-associated virus (AAV) therapies.  NanoTemper Technologies has launched its Spectral Shift technology to remove the roadblocks experienced by scientists dealing with really complex molecular interactions often… Read More

#News

#AAV #Biotechnology #Diabetes #Precision medicine

Collaboration to develop AAV vectors for diabetes gene therapy 

PerkinElmer’s SIRION Biotech business and the Centre for Genomic Regulation (CRG) have agreed to jointly develop new generation adeno-associated virus (AAV) vectors for Type 1 and Type 2 diabetes gene therapy in the pancreas.  The collaboration  The collaboration combines SIRION’s AAV technology platform and expertise… Read More

#News